These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 37837549)

  • 1. GPR37 expression as a prognostic marker in gliomas: a bioinformatics-based analysis.
    Liang K; Guo Z; Zhang S; Chen D; Zou R; Weng Y; Peng C; Xu Z; Zhang J; Liu X; Pang X; Ji Y; Liao D; Lai M; Peng H; Ke Y; Wang Z; Wang Y
    Aging (Albany NY); 2023 Oct; 15(19):10146-10167. PubMed ID: 37837549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
    Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
    BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PROS1 shapes the immune-suppressive tumor microenvironment and predicts poor prognosis in glioma.
    Wang J; Wu N; Feng X; Liang Y; Huang M; Li W; Hou L; Yin C
    Front Immunol; 2022; 13():1052692. PubMed ID: 36685506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MCM10 as a novel prognostic biomarker and its relevance to immune infiltration in gliomas.
    Tian QS; Zhang Q; Huang W
    Technol Health Care; 2023; 31(4):1301-1317. PubMed ID: 36872806
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Liu YJ; Zeng SH; Qian WH; Tao MX; Zhu YY; Li JP
    Pharmgenomics Pers Med; 2022; 15():261-275. PubMed ID: 35370417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
    Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
    Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated LILRB1 expression predicts poor prognosis and is associated with tumor immune infiltration in patients with glioma.
    Zou R; Zhong X; Liang K; Zhi C; Chen D; Xu Z; Zhang J; Liao D; Lai M; Weng Y; Peng H; Pang X; Ji Y; Ke Y; Zhang H; Wang Z; Wang Y
    BMC Cancer; 2023 May; 23(1):403. PubMed ID: 37142967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EFNA1 is a potential key gene that correlates with immune infiltration in low-grade glioma.
    Hao YP; Wang WY; Qiao Q; Li G
    Medicine (Baltimore); 2021 Jun; 100(22):e26188. PubMed ID: 34087884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PLEKHA4 Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Glioma.
    Zhang W; Li L; Bian PP; Luo QP; Xiong ZT
    Biomed Res Int; 2023; 2023():4504474. PubMed ID: 36714030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pro-invasive factor COL6A2 serves as a novel prognostic marker of glioma.
    Zhu J; Lin Q; Zheng H; Rao Y; Ji T
    Front Oncol; 2022; 12():897042. PubMed ID: 36505882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MELK is a prognostic biomarker and correlated with immune infiltration in glioma.
    Yang H; Zhou H; Wang G; Tian L; Li H; Zhang Y; Xue X
    Front Neurol; 2022; 13():977180. PubMed ID: 36353126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Siglec15 is a prognostic indicator and a potential tumor-related macrophage regulator that is involved in the suppressive immunomicroenvironment in gliomas.
    Wang J; Xu L; Ding Q; Li X; Wang K; Xu S; Liu B
    Front Immunol; 2023; 14():1065062. PubMed ID: 37325664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of tumor-associated macrophages and PD-L1 in patients with hepatocellular carcinoma and construction of a prognostic model.
    Kong P; Yang H; Tong Q; Dong X; Yi MA; Yan D
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10685-10700. PubMed ID: 37306737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TGIF2 is a potential biomarker for diagnosis and prognosis of glioma.
    Zhang W; Zhang L; Dong H; Peng H
    Front Immunol; 2024; 15():1356833. PubMed ID: 38629068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MCM4 is a novel prognostic biomarker and promotes cancer cell growth in glioma.
    Yang S; Yuan Y; Ren W; Wang H; Zhao Z; Zhao H; Zhao Q; Chen X; Jiang X; Zhang L
    Front Oncol; 2022; 12():1004324. PubMed ID: 36465369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL4I1 in M2-like macrophage promotes glioma progression and is a promising target for immunotherapy.
    Ye F; Wang L; Li Y; Dong C; Zhou L; Xu J
    Front Immunol; 2023; 14():1338244. PubMed ID: 38250074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Profiles of immune-related genes and immune cell infiltration in the tumor microenvironment of diffuse lower-grade gliomas.
    Deng X; Lin D; Zhang X; Shen X; Yang Z; Yang L; Lu X; Yu L; Zhang N; Lin J
    J Cell Physiol; 2020 Oct; 235(10):7321-7331. PubMed ID: 32162312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of PIMREG in the prognosis and response to immune checkpoint blockade of glioma patients.
    Zhu H; Hu X; Feng S; Gu L; Jian Z; Zou N; Xiong X
    Front Immunol; 2022; 13():946692. PubMed ID: 35928818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High expression of PCOLCE gene indicate poor prognosis in patients and are associated with immune infiltration in glioma.
    Guo Q; Gao X; Li J; Liu Y; Liu J; Yang H; Cui M; Zhang M; Duan L; Ma X
    Sci Rep; 2023 Mar; 13(1):3820. PubMed ID: 36882457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.
    Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J
    BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.